NDAINJECTIONINJECTABLEPriority Review
Approved
Mar 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 4h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Iobenguane Sulfate I-131 is a radioiodinated agent administered by injection used for diagnostic and therapeutic imaging in nuclear medicine. The drug localizes to neuroendocrine tissues and tumors, enabling visualization and treatment of certain malignancies. It represents a niche radiopharmaceutical with specialized clinical applications.
LOE Approaching
Product approaching loss of exclusivity with limited indicated patient population; expect declining commercial operations and smaller dedicated team size.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Iobenguane Sulfate I-131 offers exposure to specialized radiopharmaceutical expertise and niche oncology markets, but with limited growth upside given LOE trajectory. Career progression will depend on willingness to support defensive/transition strategies and transition to emerging radiopharmaceutical programs.
Medical Science LiaisonProduct Manager
Worked on IOBENGUANE SULFATE I 131 at PharmaLundensis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.